Acer Therapeutics Inc.: Nasdaq/NYSE listing notice — Acer Therapeutics faces Nasdaq delisting risk from bid price and MVLS deficiencies

Acer Therapeutics Inc.

Received bid price deficiency notice June 5, 2023; must close at $1.00+ for 10 consecutive business days by Dec 4, 2023.
Received MVLS deficiency notice May 3, 2023; MVLS must be $35M+ for 10 consecutive business days by Oct 30, 2023.
May also cure MVLS deficiency by meeting minimum stockholders' equity of $2.5 million.
If not cured by deadlines, eligible for additional 180-day bid price cure period or delisting appeal.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Acer Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

June 5, 2023, Acer Therapeutics Inc. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Bid Price Deficiency Notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Capital Market under

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-026809

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.